Similar articles

• [Clinical research on the aged concerning the anti-sclerotic effect of a new heparinoid extract: glycuronoglucosaminoglycan sulfate (3GS)].

  Turpini R, Caliandro L, Cocchi A, Volpi F, Brusaioli G, Grignani G, Antognetti R. Turpini R, et al. Clin Ter. 1975 May 15;73(3):213-36. Clin Ter. 1975. PMID: 123842 Italian. No abstract available.
• [Effect of a heparinoid extract on the blood lipids and basal thrombodensitogram].

  Ferri F, D'Agostino F, D'Onofrio E. Ferri F, et al. Minerva Med. 1973 Jan 27;64(6):272-7. Minerva Med. 1973. PMID: 4120079 Italian. No abstract available.
• [Glucuronyl-glucosaminoglycan sulfate in therapy of atheroarteriosclerotic syndromes in geriatrics].

  Bompani R, Violi G. Bompani R, et al. Minerva Med. 1974 Nov 21;65(83):4315-29. Minerva Med. 1974. PMID: 4279362 Italian. No abstract available.
• Heparin, non-heparin glycosaminoglycans, and heparinoids: an overview of their application in atherosclerosis.

  Engelberg H. Engelberg H. Semin Thromb Hemost. 1991;17 Suppl 1:5-8. Semin Thromb Hemost. 1991. PMID: 1712511 Review. No abstract available.
• Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.

  Polli EE, Cortellaro M. Polli EE, et al. Haematologica. 1980 Jun;65(3):361-9. Haematologica. 1980. PMID: 6778788 Review. No abstract available.